Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: ICU Medical is a developer and manufacturer of proprietary, disposable medical connection systems for intravenous (IV) therapy. The Company's primary product is the CLAVE(R), a needleless IV connector designed to prevent accidental needlesticks and disconnections. The Company also manufactures protected needle products (Click Lock, Piggy Lock) and distributes custom IV sets through its subsidiary, Budget Medical Products, Inc. (BMP). Sales are conducted through independent distributors and strategic agreements with major manufacturers B.Braun/McGaw and Abbott Laboratories.
Key Financial Metrics (Fiscal Year 1998)
| Metric | 1998 | 1997 | 1996 |
|---|---|---|---|
| Net Sales | $39,842,000 | $30,404,000 | $24,599,000 |
| Gross Profit | $23,155,000 | $17,587,000 | $14,161,000 |
| Gross Margin | 58% | 58% | 58% |
| Operating Income | $10,014,000 | $7,862,000 | $5,925,000 |
| Operating Margin | 25% | 26% | 24% |
| Net Income | $7,222,000 | $5,682,000 | $4,739,000 |
| Diluted EPS | $0.86 | $0.71 | $0.54 |
| Cash Flow from Operations | $6,574,000 | $8,666,000 | $6,513,000 |
| Cash and Liquid Investments | $38,090,000 | $35,112,000 | $31,760,000 |
| Working Capital | $43,817,000 | $37,993,000 | $35,587,000 |
| Long-term Debt | $0 | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 31% to $39.8 million, driven primarily by a 41% increase in CLAVE product sales ($27.5 million). Unit shipments of CLAVE products rose 88%, though the average selling price decreased approximately 25% due to pricing pressure and a shift toward bulk sales.
- Customer Concentration: Sales concentration increased significantly. B.Braun/McGaw accounted for 35% of net sales (up from 36% in 1997 but with higher volume), while Abbott accounted for 29% (up from 16% in 1997). Independent distributors' share dropped to 36% from 48%.
- Product Mix Shift: Sales of protected needle products (Click Lock, Piggy Lock) declined 29% as the market shifts to needleless technology. Conversely, the subsidiary BMP saw sales grow to $3.2 million from $1.8 million.
- Expenses: Selling, General, and Administrative (SG&A) expenses rose 43% to $12.1 million, increasing as a percentage of sales from 28% to 30%, primarily due to marketing expansion and legal fees. Research and Development (R&D) expenses decreased slightly to $1.0 million.
- Legal Contingency: The Company accrued a provision of approximately $728,000 regarding a jury verdict in a commission dispute (Allen Petty v. ICU Medical), which is currently under appeal.
Guidance, Outlook, and Risks
- Outlook: Management expects sales to continue growing in 1999, driven by expanded agreements with Abbott and B.Braun/McGaw. However, they anticipate continued declines in average unit selling prices and expect gross margins to remain equal to or slightly lower than 1998 levels.
- Capital Expenditures: Significant capital spending is expected in 1999 for production tooling, machinery, and facility expansion in San Clemente to support increased volumes and automation.
- Key Risks:
- Customer Dependence: The loss of B.Braun/McGaw or Abbott could have a material adverse effect due to their dominance in hospital contracts.
- Competition: Intense competition from large manufacturers (Baxter, Abbott, B.Braun) and new entrants developing similar needleless connectors.
- Regulatory: FDA clearance is required for new products (e.g., CLC 2000); delays or denials could impact growth.
- Patent Litigation: Risks associated with defending patents or potential infringement claims.
- Year 2000 (Y2K): While IT systems are believed compliant, non-IT manufacturing systems are still being assessed, and third-party compliance is uncertain.
Investor Verification Checklist
- Customer Concentration: Verify the stability of contracts with B.Braun/McGaw and Abbott, which together represent 64% of 1998 revenue.
- Pricing Pressure: Monitor the trend of declining average selling prices for CLAVE products and whether volume growth continues to offset price erosion.
- Legal Exposure: Track the status of the appeal regarding the $728,000 judgment in the Allen Petty case.
- Product Transition: Assess the rate of decline in protected needle product sales versus the growth of needleless alternatives.
- Capital Allocation: Review upcoming capital expenditures for the Mexico facility and San Clemente expansion to ensure they align with projected sales growth.